***antisoma*** woher kommen die hohen umsätze??? - 500 Beiträge pro Seite

[brokeattack]

weiß jmd was genaueres.
thanxx

[GRILLER]

fetter bericht im aktionär mit kursziel 20 euro auf sicht von 2 jahren!

coole sache

the sky is the limit

[eaglemen]

Dann schaut euch mal lieber die andere Förtsch aktie an:
Illumina 927079 die kommen im Hoch von 150€,haben schon die 38er durchbrochen und sind auf dem besten Weg auch die 100Tagel.zu nehmen.Für mich ein klares strong by!

[eaglemen]

Gibt es bei Illumina was neues,oder wollen die in einer Woche auf 20€ stehen?

[eaglemen]

up!

[eaglemen]

Beide heute mit Gewinn Mitnahmen,hält sich aber in Grenzen.Da ich beide im Depot habe (Illumina etwas höher gewichtet)solte es mir auch egal sein welche schneller steigt,aber steigen werden sie wohl beide.
Klares strong by für beide!Illumina 927079 und Antisoma 917990

[eaglemen]

Uff, zum Glück habe ich am Montag komplet in Illumina umgeschichtet.Würde nur gerne wissen was bei Antisoma los ist heute?
Grüsse

[rayvogel]

RNS Number:7689E
Antisoma PLC
6 June 2001

Recruitment to Phase III study of Antisoma`s lead product pemtumomab extended
after initial target achieved



6 June 2001, London, UK - Antisoma plc, the UK-based biopharmaceutical
company, today announces its intention to extend recruitment to the Phase III
SMART study of pemtumomab (formerly known as Theragyn) in the treatment of
ovarian cancer following a meeting with the US Food and Drug Administration
(FDA). Recruitment has now reached the initial target of 300 patients.



The SMART study is designed to confirm that treatment of certain ovarian
cancer patients with Yttrium-90 radiolabelled pemtumomab, in addition to
current standard care, demonstrates a statistically significant survival
benefit over standard care alone. The protocol was based on the survival
advantage shown in the Phase II study. At a 5 June 2001 meeting, the Company
was advised by the FDA that, to be considered for any future marketing
approval, the level of statistical significance that the data must demonstrate
should be increased to p<0.01 from the original study design of p<0.05. As a
result the total number of events required to demonstrate the revised level of
statistical significance has risen from 80 to 116. An additional, but as yet
undetermined, number of patients will be recruited to achieve this new end
point.



An independent committee set up to monitor safety and other data in the SMART
study has indicated that overall mortality for the total study population
(i.e. treated and control patients together) is lower than had been expected
at this stage of the study.



As a consequence of the requirement for greater statistical significance,
additional recruitment and the lower initial mortality rates, the projected
date of filing for any marketing approval will be later than previously
expected and is now unlikely to be before 2004. A mechanism will be agreed
with the FDA that will enable a more accurate assessment of timelines later
this year without compromising the integrity of the study.



Glyn Edwards, Antisoma`s Chief Executive Officer, commented, "The delay in
obtaining a result for the study should ultimately benefit patients by
providing a more robust result. The lower overall death rate in the study so
far may be consistent with the stringent eligibility criteria for entry of
patients into SMART, improvements in standard care treatment or potentially
some greater effect from pemtumomab. At this stage it is not possible to
determine which, if any, of these factors is contributing to the lower death
rates experienced to date. We are pleased to have reached our original target
of 300 patients and will work hard to complete the additional enrolment and
achieve final results in the shortest possible time."



An investor conference call will take place today at 9.30 am UK time / 4.30am
CET. Please contact Claire Rowell on [phone] for details.

Enquiries:

Antisoma plc
Glyn Edwards, Chief Executive Officer Tel: [phone]
Val Tate, Head of Investor Relations


LONDON (AFX) - Antisoma PLC said it has extended recruitment to a Phase III
SMART study of its lead product, pemtumomab, in the treatment of ovarian cancer
after it achieved its initial target of 300 patients.
The SMART study is designed to confirm that treatment of certain ovarian
cancer patients with Yttrium-90 radiolabelled pemtumomab, in addition to current
standard care, demonstrates a statistically significant survival benefit over
standard care alone, said Antisoma.
Antisoma said an independent committee set up to monitor safety and other
data in the SMART study has indicated that overall mortality for the total study
population is lower than had been expected at this stage of the study.
As a consequence of the requirement for greater statistical significance,
additional recruitment and the lower initial mortality rates, the projected date
of filing for any marketing approval will be later than previously expected and
is now unlikely to be before 2004, said Antisoma.
slm/

[MBroker]

Ganz toll, die englischen Texte kopieren und den fertig. Das ist für Anleger unheimlich sinning. Statt das man einfach sagt, dass es noch bis 2004 dauert bis das Medikament pemtumomab (z. zt. Phase III) an den Markt kommt.